How much compute power do you need to analyze 10 gene panels, exomes, or genomes each day? What about 1,000 genomes each week?
Questions about compute infrastructure are among the most common we hear from our customers, and this has been the primary motivator for our collaboration with Intel. Together, we’ve been working to support affordable, massively scalable whole-genome analysis based on Intel’s world-class infrastructure and our industry-leading analysis tools.
Earlier this year we released the reference architecture that came from this collaboration, and you can learn more about it in the webinar below featuring Michael McManus, Senior Health & Life Sciences Solution Architect at Intel, and Mikael Flensborg, Director and Solution Lead for QIAGEN Bioinformatics. The speakers will update you on the new architecture, which combines our Biomedical Genomics Solution with the Intel Scalable System Framework. They’ll also share advice on sizing and building a genomics cluster based on data-generation needs, as well as how to scale the cluster as demand changes.
The solution represents some of the code optimization work that Intel has focused on lately, teaming up with industry leaders such as QIAGEN Bioinformatics to improve algorithms based on the latest multi-core chip architecture. As genome analysis tools become increasingly complex — newer haplotype-aware callers, for instance, are far more computationally intense than older generations of variant callers — there is greater need for scientists to become experts in computational infrastructure. With solutions like the QIAGEN/Intel reference architecture, we alleviate that burden by recommending a scalable, easily managed system that allows users to focus instead on the science.
For example, this system meets the computational and analysis demands of Illumina’s HiSeq X Ten while providing whole-genome analysis for as little as $22 per genome. With Intel’s 32-node cluster, researchers can save as much as $1.3 million in total ownership costs compared to a vendor-recommended BWA+GATK variant calling pipeline run on an 85-node cluster.
Learn more about our High volume sequencing solution
Reference Architectures for the QIAGEN Biomedical Genomics Solution
https://clcbio.23video.com/12438081.ihtml/player.html?token=9c8598703736f4ebfb60db5c2669f27b&source=embed&photo%5fid=14250926
At Bio-IT World we had the pleasure to demonstrate the results of our work with the information technology leaders Intel and BioTeam.
Our collaborations create infrastructure solutions that make population-scale genomic analysis feasible for more researchers. We’ve been working together with Intel to bring world-class infrastructure together with industry-leading genome analysis tools to enable massively scalable whole genome analysis at lower cost. Together with BioTeam we're creating a proof-of-concept high-performance computing (HPC) appliance.
For more details about the partnerships, please read the official press release below.
QIAGEN partners with IT leaders on novel infrastructure for genomics
Demonstrates high-performance computing and genome analysis solutions at Bio-IT World
“By combining our industry-leading genome analysis applications with hardware solutions from leaders like Intel and BioTeam, QIAGEN Bioinformatics is providing world-class infrastructure to help scientists reveal actionable insights from genomic data,” said Dr. Laura Furmanski, Senior Vice President and head of QIAGEN’s Bioinformatics Business Area. “While next-generation sequencing is a momentous advance, society cannot realize the full potential without a corresponding ability to analyze NGS data quickly and accurately. Researchers and clinicians need cost-effective, comprehensive tools for calling and interpreting variants across whole human genomes, and we are providing these novel solutions.”
QIAGEN’s collaboration with Intel developed a reference architecture designed to produce high-volume whole genome data analysis, keeping up with the world’s highest-capacity sequencers, helping NGS scientists keep their sequencing pipelines running smoothly and efficiently. This offering leverages QIAGEN’s CLC Genomics Server software on a compute cluster of 32 Intel® Xeon® processor E5 family based nodes. It provides built-in analysis tools, scalability, fast connection and parallel storage, using Intel Enterprise Edition for Lustre, the world’s largest parallel storage system. In tests, the solution analyzed data quickly and for as little as $22 per genome. It will be described in a conference presentation at Bio-IT World from 3:30-3:50 p.m. on April 6.
“The collaboration with QIAGEN Bioinformatics targets the vexing challenges presented by soaring demand for genome analysis, commonly faced by NGS scientists,” said Ketan Paranjape, GM Life Sciences at Intel. “Optimized solution architectures for these workloads enable researchers to keep pace as sequencers process more genomes than we could have imagined, even a few years ago — all while taking advantage of open systems to save money as well.”
BioTeam and QIAGEN’s proof-of-concept appliance packages CLC Genomics Server with the BioTeam Appliance scientific computing platform to provide a cost-effective, high-performance offering. The flexible, customizable solution delivers a system that maps the computational requirements of the CLC Bio software to an infrastructure that complements its capabilities. The BioTeam Appliance demo at Bio-IT World will be at the QIAGEN Bioinformatics booth (#229) from 1:30-1:45 p.m. on April 6.
“Bioinformatics is an ideal market for high-performance computing, and our simple, end-to-end appliance removes a significant barrier to adoption for many customers,” said Stan Gloss, Founding Partner and Chief Executive Officer at BioTeam. “Our plug-and-play solution enables scientists to focus on research rather than on creating complex IT systems from scratch. We look forward to continuing development of this proof-of-concept model with the QIAGEN Bioinformatics team.”
About BioTeam
BioTeam is a high-performance consulting practice dedicated to delivering objective, technology agnostic solutions to the life science researchers. We leverage the right technologies customized to our client’s unique needs in order to enable them to reach their scientific objectives.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
